Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Insider trades › Ars Pharmaceuticals › Officer received an award of 1.2M SPRY derivative securities Insider trades
Why it stands out Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Transaction date Nov 2, 2026
Reporting period Not applicable
Filed with the SEC Nov 4, 2026 Officer Grant / award
Context Classification grant award
Code A — grant or award
Planned / mechanical clue Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID 0001475990-26-000009
Filed / recorded
Nov 4, 2026, 9:18 PM UTC
Added to OQRO Nov 4, 2026, 9:20 PM UTC
Data quality Verified: identifiers matched exactly
Issuer ARS Pharmaceuticals, Inc.
Reporting person John L Slebir
Officer title Chief Legal Officer
Security Stock Option (right to buy)
Table Derivative (Table II)
Transaction date Nov 2, 2026
Acquired / disposed Acquired (A)
Shares owned after 1,199,482
Footnotes from the filing 25% of the shares subject to the option vest on October 26, 2027, and the remaining shares will vest monthly thereafter over three years. The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
What came next Nov 5, 2026 Company filing · Form 8-K · Results Reported its results